Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
Michael A Henderson, Bryan H Burmeister, Jill Ainslie, Richard Fisher, Juliana Di Iulio, B Mark Smithers, Angela Hong, Kerwin Shannon, Richard A Scolyer, Scott Carruthers, Brendon J Coventry, Scott Babington, Joao Duprat, Harald J Hoekstra, John F Thompson
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2015
Awarded by National Health and Medical Research Council of Australia
The National Health and Medical Research Council of Australia (project IDs 251732 and 454745), Cancer Council Australia, Melanoma Institute Australia, and the Cancer Council South Australia.